	US 11,963,968 B2
	Treatment of hearing loss
Zheng-Yi Chen, Somerville, MA (US); Wenyan Li, Boston, MA (US); and Yi-Zhou Quan, Dorchester, MA (US)
Assigned to Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed on Jan. 13, 2023, as Appl. No. 18/154,474.
Application 18/154,474 is a continuation of application No. 16/964,882, granted, now 11,590,152, previously published as PCT/US2019/015348, filed on Jan. 28, 2019.
Claims priority of provisional application 62/622,598, filed on Jan. 26, 2018.
Prior Publication US 2023/0277574 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7028 (2006.01); A61K 31/19 (2006.01); A61K 31/365 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/7028 (2013.01) [A61K 31/19 (2013.01); A61K 31/365 (2013.01); A61K 45/06 (2013.01)]

6 Claims

1. A method of regenerating inner ear cells in a mature mammalian cochlea in a subject in need thereof, comprising contacting the cochlea with an effective amount of at least one activator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells; thereby regenerating the inner ear cells in mature mammalian cochlea; wherein the mTOR activator comprises mhy1485, 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one (3BDO), salidroside, or polynucleotides encoding mTOR.